Age-standardized pancreatic cancer mortality rates have not improved since 2010-2014.
-
EU 2021 cancer mortality trends differ between men and women -
FDA approves cemiplimab for basal cell carcinoma The approval is based on an open-label, phase 2 trial.
-
NICE approves routine use of nivolumab for metastatic melanoma An appeals period will run until February 26, with the final guidance to be published next month
-
High-risk SCC: gene test could help inform management decisions Management of SCC is guided by the risk for metastasis.
-
Physicians express reservations about social media for cancer trial enrollment Many believe social media increases patient awareness, education, and access.
-
Conjunctival melanoma may be attributed to UV radiation Genetic changes are similar to those associated with skin melanoma.
-
Melanoma: primary prevention averted more deaths vs early detection Australian cost-effectiveness study shows primary prevention is low cost and effective.
-
Advanced melanoma: up-front immunotherapy most cost-effective Nivolumab monotherapy least expensive compared to other regimens.
-
CLL/NHL: pigment traits, sun sensitivity associated with greater risk French study suggests a partly common genetic etiology with keratinocyte carcinoma.
-
Cancer: new drugs averted 1.2 million US deaths Mortality changes were most prevalent for cancer types with more approvals.
-
NICE guidance on nivolumab for advanced melanoma The draft decision is open for public comment until November 25, 2020
-
Immunotherapy: real-world outcomes do not measure up to clinical trial results Patients in the real world differ from those included in clinical trials.
-
Skin cancer drug not cost-effective for routine NHS use Nivolumab fails to secure NICE approval for adjuvant treatment of resected melanoma with lymph node involvement or metastatic disease.
-
Tazemetostat shows activity in skin and blood cancer Tazemetostat received accelerated FDA approval based on these findings.